Background {#Sec1}
==========

Lung cancer is the most common cause of cancer-related deaths, and non-small cell lung cancer (NSCLC) accounts for approximately 85 % of all lung cancers \[[@CR1], [@CR2]\]. Over 70 % of patients with NSCLC have advanced disease at the time of diagnosis, and prognosis is generally poor \[[@CR3]\]. Recently, molecular targeted therapies have been developed and have provided a remarkable benefit to NSCLC patients with specific genetic alterations. In particular, NSCLC with mutation in the epidermal growth factor receptor (EGFR) gene are sensitive to EGFR blockade with specific tyrosine kinase inhibitors (TKIs). EGFR-TKIs are efficacious in patients with NSCLC harboring *EGFR* mutations as demonstrated in prospective clinical trials \[[@CR4]--[@CR8]\]. However, in spite of this efficacy almost all patients with *EGFR*-mutant NSCLC develop resistance to EGFR-TKIs.

Various mechanisms of resistance to EGFR-TKIs have been identified, and understanding these is critical for development of effective treatment strategies for EGFR-TKI-resistant NSCLC. The major mechanism of acquired resistance reported is secondary T790M mutation on exon 20 on the *EGFR* gene \[[@CR9]--[@CR12]\]. This secondary mutation enhances ATP-binding affinity of *EGFR*-mutated cells. Since EGFR-TKIs are competitive ATP-inhibitors, their efficacy is decreased in the face of the T790M mutation \[[@CR13]\]. Additional mechanisms include amplification of the *MET* gene \[[@CR11], [@CR12], [@CR14]\], *PIK3CA* mutation \[[@CR11], [@CR15]\], *BRAF* mutation \[[@CR16]\], epithelial-to-mesenchymal transition (EMT) \[[@CR11]\], and small cell lung cancer (SCLC) transformation \[[@CR11], [@CR12]\].

Several studies have examined the mechanisms and frequency of EGFR-TKI resistance, though minimal data regarding Japanese patients exist. Furthermore, the clinical factors that influence the frequency of acquired resistance mutations, especially T790M, remain unclear. This study aimed to analyze the causes of acquired resistance to EGFR-TKIs in Japanese patients with NSCLC, and to evaluate clinical factors related the frequency of T790M mutation.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

We reviewed the medical records of consecutive patients with NSCLC harboring *EGFR* mutations who had undergone rebiopsies based on physician's decision in the cases of acquired resistance to EGFR-TKI. Most rebiopsy samples were obtained from sites assessed as disease progression by imaging. Patients were treated at the Shizuoka Cancer Center between September 2002 and August 2014. Acquired resistance was defined according to Jackman's criteria \[[@CR17]\]. The criteria defined acquired resistance as progression while receiving EGFR-TKI, after initial response or durable stable disease (\>6 months). The written informed consent regarding *EGFR* mutational analysis was obtained from most patients, and verbal informed was from some patients since *EGFR* mutational analysis was performed under the Japanese insurance system. Additionally, some patients were enrolled in the Shizuoka Lung Cancer Mutation Study \[[@CR18]\], and these samples were analyzed using our tumor genotyping panel. This study protocol was approved by the Institutional Review Board of Shizuoka Cancer Center under number 27--J102--27--1--3.

Mutational profiling {#Sec4}
--------------------

A tumor genotyping panel was designed to assess 23 hotspot sites of genetic alterations in 9 genes (*EGFR*, *KRAS*, *BRAF*, *PIK3CA*, *NRAS*, *MEK1*, *AKT1*, *PTEN*, and *HER2*), gene copy number of *EGFR*, *MET*, *PIK3CA*, *FGFR1*, and *FGFR2*, and *ALK*, *ROS1*, and *RET* fusions using pyrosequencing plus capillary electrophoresis, quantitative polymerase chain reaction (PCR), and reverse transcription PCR, respectively (Table [1](#Tab1){ref-type="table"}). We analyzed samples from patients enrolled in the Shizuoka Lung Cancer Mutation Study, using this tumor genotyping panel. The other samples were analyzed for *EGFR* mutations using the Scorpion ARMS or Cycleave methods by a commercial clinical laboratory (SRL Inc., Tokyo, Japan) (see Additional file [1](#MOESM1){ref-type="media"}).Table 1Multiplexed tumor genotyping panelGene namePositionAA mutantNucleotide mutantEGFRG719G7192155G \> T/AG719A2156G \> Cexon 19DeletionT790T790M2369C \> Texon20InsertionL858L858R2573 T \> GL861L861Q2582 T \> AKRASG12G12C/S/R34G \> T/A/CG12V/A/D35G \> T/C/AG13G13C/S/R37G \> T/A/CG13D/A38G \> A/CQ61Q61K181C \> AQ61R/L182A \> G/TQ61H183A \> T/CBRAFG466G466V1397G \> TG469G469A1406G \> CL597L597V1789C \> GV600V600E1799 T \> APIK3CAE542E542K1624G \> AE545E545K/Q1633G \> A/CH1047H1047R3140A \> GNRASQ61Q61K181C \> AQ61L/R182A \> T/GMEK1 (MAP2K1)Q56Q56P167A \> CK57K57N171G \> TD67D67N199G \> AAKT1E17E17K49G \> APTENR233R233697C \> THER2exon20Insertion

Evaluation of efficacy {#Sec5}
----------------------

Responsiveness to EGFR-TKI treatment was evaluated according to the Response Evaluation Criteria in Solid Tumors version 1.1 \[[@CR19]\]. Progression-free survival (PFS) was defined as the period between the start of EGFR-TKI treatment and progressive disease or death from any cause. Overall survival (OS) was defined as the period between the start of EGFR-TKI treatment and the date of death from any cause.

Statistical analysis {#Sec6}
--------------------

All categorical variables were analyzed by the chi-square test or Fisher's exact test, as appropriate. Continuous variables were analyzed using the Mann-Whitney test. Logistic regression analyses were used to adjust for potential confounding factors. All *p* values \< 0.05 were considered statistically significant. All analyses were performed using JMP 10 for Windows statistical software (SAS Institute Japan Inc., Tokyo, Japan).

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

Sixty-one patients with NSCLC harboring *EGFR* mutations, and who had undergone rebiopsy after acquired resistance to EGFR-TKI at the Shizuoka Cancer Center were included in this study. Patient characteristics are shown in Table [2](#Tab2){ref-type="table"}. The median age (range) was 64 (39--84) years, and most patients were female (72 %) and never-smokers. All patients had been diagnosed with adenocarcinoma of the lung with activating *EGFR* mutations at initial diagnosis. The types of *EGFR* mutations before the initial EGFR-TKI treatment were exon 19 deletion in 37 patients (61 %), exon 21 L858R in 19 patients (31 %), and other/double *EGFR* mutations in five patients (8 %). Thirty-nine patients (64 %) were treated with EGFR-TKI as first-line therapy. Twenty-two patients (36 %) received EGFR-TKI as second or subsequent-line therapy. Forty-nine patients (80 %) were treated with gefitinib, seven patients (12 %) with erlotinib, and five patients (8 %) with other EGFR-TKIs including afatinib. All patients received EGFR-TKI monotherapy. Twenty patients received continuous treatment with EGFR-TKI more than 30 days after disease progression, and 41 patients finished EGFR-TKI treatment within 29 days after diagnosis of disease progression.Table 2Patient characteristics analyzed in our study (*n* = 61)Age, year Median64 Range39--84Sex, n (%) Female44 (72 %) Male17 (28 %)Smoking history, n (%) Never44 (72 %) Former/Current17 (28 %)ECOG performance status, n (%) 0--152 (85 %) 2--49 (15 %)Pretreatment EGFR status, n (%) Exon19 deletion37 (61 %) Exon21 L858R19 (31 %) Other5 (8 %)EGFR TKI, n (%) Gefitinib49 (80 %) Erlotinib7 (12 %) 2nd generation5 (8 %)Abbreviations: *ECOG* eastern cooperative oncology group, *EGFR* epidermal growth factor receptor, *TKI* tyrosine kinase inhibitor

Rebiopsy {#Sec9}
--------

Table [3](#Tab3){ref-type="table"} depicts characteristics of rebiopsy sites, specimens, and procedures in patients who had undergone rebiopsy after developing acquired resistance to EGFR-TKIs. Because of their easy accessibility and practical necessity, serous effusions such as pleural effusion and cerebrospinal fluid account for more than half of the specimens. Pulmonary lesions were also rebiopsied, with the most common procedure being transbronchial biopsy. Biopsy samples from lymph nodes or other sites were obtained using computed tomography-guided or sonography-guided needle biopsy. All rebiopsies were performed after stopping EGFR-TKI treatment.Table 3Procedures and specimens of rebiopsy samples obtained from NSCLC patients with *EGFR* mutationsProcedure and specimenNumberSurgery Brain3 Lung2 Autopsy1Biopsy Lung15 Lymph node3 Other4Fluid Pleural effusion24 Cerebrospinal fluid8 Cardiac effusion1

Resistance mechanisms {#Sec10}
---------------------

A total of 61 rebiopsy samples were analyzed for EGFR mutations. Twenty-seven rebiopsy samples were analyzed using our tumor genotyping panel, and 34 samples were examined for *EGFR* mutations by commercial clinical laboratories. All of 61 patients had *EGFR* activating mutations before EGFR-TKI treatment, and 55 patients (90.2 %) still had same *EGFR* mutations in rebiopsy samples. T790M mutation was identified in 21 of 61 samples (34.4 %; Fig. [1](#Fig1){ref-type="fig"}). No samples had small cell histologic transformation. In samples analyzed using our tumor genotyping panel, *MET* gene copy number gain was seen in two of 27 samples (7 %). Additionally, we detected *PIK3CA* mutation (E542K), *BRAF* mutation (G466V), and *KRAS* mutation (G12D), in one sample each in 27 samples (4 %) (Fig. [2](#Fig2){ref-type="fig"}). Six of 61 rebiopsy samples (9.8 %) did not possess *EGFR* mutation, despite having EGFR activating mutations at the initial analysis. *KRAS* mutation was detected in 1 of these samples.Fig. 1Frequency of T790M mutation in rebiopsy samples (*n* = 61) Fig. 2Multimutational profiling in rebiopsy samples analyzed using our tumor genotyping panel (*n* = 27). CNG: Copy number gain

T790M prevalence {#Sec11}
----------------

Correlations between patient characteristics and T790M prevalence were evaluated (Table [4](#Tab4){ref-type="table"}). Eleven of 20 patients who received continuous treatment with EGFR-TKI after disease progression had T790M mutation in the rebiopsy sample. However, only 10 of 41 patients who had finished EGFR-TKI treatment at the time of disease progression had T790M mutation (Fig. [3](#Fig3){ref-type="fig"}). The frequency of T790M mutation in patients who received continued treatment with EGFR-TKI after disease progression was significantly higher than in patients who finished EGFR-TKI at diagnosis of disease progression (55 % versus 24 %, *p* = 0.018). Multivariate analysis also demonstrated that continuous treatment with EGFR-TKI after disease progression was significantly correlated with T790M mutation (Table [4](#Tab4){ref-type="table"}). Other characteristics, including PFS with EGFR-TKI, rebiopsy site, and rebiopsy sample, had no statistical association with the prevalence of T790M.Table 4Multivariate and univariate analyses of patient characteristics and T790M prevalence in patients with NSCLC harboring *EGFR* mutations, who had undergone rebiopsy after acquired resistance to EGFR-TKI (*n* = 61)Patient characteristicsNumberT790M (%)*P* (Univariate)*P* (Multivariate)Age0.9292 ≥75124 (33 %) \<744917 (35 %)Sex0.4904 Female4414 (32 %) Male177 (41 %)Smoking history0.4904 Never4414 (32 %) Former/current177 (41 %)EGFR mutation status0.1038 Exon19 deletion379 (24 %) Exon21 L858R199 (47 %) Other53 (60 %)Rebiopsy site0.58130.9133 Central nervous system113 (27 %) Other5018 (36 %)Rebiopsy sample0.20170.5016 Tissue2812 (43 %) Fluid339 (27 %)EGFR TKI0.1208 Gefitinib4917 (35 %) Erlotinib74 (57 %) 2nd generation50 (0 %)Line of EGFR-TKI0.4235 1st3912 (31 %) 2nd or later229 (41 %)History of platinum doublet until rebiopsy0.7021 Yes3411 (32 %) No2710 (37 %)PFS with EGFR-TKI0.4823 ≥10 months3413 (38 %) \<10 months278 (30 %)Interval between RECIST PD and rebiopsy0.2766 ≥4 months2912 (41 %) \<4 months329 (28 %)Period of continuation of TKI beyond PD0.01820.0417 ≥30 days2011 (55 %) \<30 days4110 (24 %)Abbreviations: *EGFR* epidermal growth factor receptor, *TKI* tyrosine kinase inhibitor, *PFS* progression free survival, *PD* progressive disease Fig. 3Relationship of EGFR-TKI continuation beyond progressive disease and T790M prevalence

Discussion {#Sec12}
==========

Previous reports from examining patients in western countries have reported *EGFR* T790M mutation in 49--69 % patients with NSCLC harboring *EGFR* mutations who had undergone rebiopsy after developing acquired resistance to EGFR-TKIs \[[@CR11], [@CR12], [@CR20]\]. In contrast, our study identified T790M mutation in only 21 of 61 rebiopsy samples (34.4 %). This finding is similar to that of the one other Japanese study we are aware of \[[@CR21]\]. Therefore, T790M prevalence in Japanese and Western patients may be different. In our study, only 30 % of patients received continuous treatment with EGFR-TKI after disease progression. Shimilarly, few such patients were included in the study from Hata et al. \[[@CR21]\]. However, 88--91 % of patients in previous studies from western countries received continuous treatment with EGFR-TKI after disease progression \[[@CR12], [@CR20]\]. Additionally, the frequency of T790M mutation in patients who received continuous treatment with EGFR-TKI after disease progression was significantly higher than that in patients who had finished EGFR-TKI treatment by diagnosis of disease progression in our study. Furthermore, the preclinical report showed that continuous exposure to EGFR-TKIs induced T790M mutation in a NSCLC cell line with an *EGFR*-sensitive mutation \[[@CR22]\]. These data suggest that continued treatment with EGFR-TKIs after disease progression may promote T790M mutation. While differences in ethnicity and analysis methods may underlie these inconsistencies, the potential for EGFR-TKIs to promote T790M mutation should not be overlooked.

The frequencies of *MET* gene copy number gain and *PIK3CA* mutation in our study were similar to those previously reported in studies from western countries \[[@CR11], [@CR12]\]. Furthermore, *BRAF* mutation is associated with acquired resistance to EGFR-TKIs \[[@CR16]\]. We also detected *KRAS* mutation in one rebiopsy sample. *KRAS* and *EGFR* mutations have previously been considered mutually exclusive \[[@CR23]\]. However, Kuiper et al. recently reported *KRAS* mutation in one rebiopsy sample following development of acquired resistance to EGFR-TKIs \[[@CR24]\]. Furthermore, Li et al. have identified double mutation of *EGFR* and *KRAS* in pretreatment assessment of NSCLC patients \[[@CR25]\]. These data suggest that *KRAS* mutation may promote acquired resistance to EGFR-TKIs through drug selective pressure. However, more data are required to confirm this hypothesis.

The availability of continuous treatment with EGFR-TKIs after disease progression is still controversial. In IMPRESS trial, continuation of gefitinib treatment after disease progression on gefitinib monotherapy did not prolong progression-free survival and overall survival in patients who received platinum-based doublet chemotherapy as subsequent line of treatment \[[@CR26]\]. However, it is unclear that the efficacy of continuous using EGFR-TKIs without platinum doublets \[[@CR27], [@CR28]\]. Recently, we had been able to use third generation EGFR-TKIs that have great efficacy for NSCLC with *EGFR* T790M mutation in clinical practice. If there are relationship between the continuous treatment with EGFR-TKIs after disease progression and the frequency of T790M, the continuous therapy can be more important choice.

Our study had several limitations. First, we retrospectively collected the data from a single institution, and our sample size was small. This small sample size results from the difficulty surrounding rebiopsy in clinical practice. Second, we analyzed only 27 rebiopsy samples (44.3 %) using our tumor genotyping panel. Therefore, further multi-institutional studies are warranted to verify our results.

Conclusions {#Sec13}
===========

The frequency of T790M mutation in rebiopsy samples in our study was lower than that reported in previous reports studies of western patients. The frequency of T790M mutation in patients who received continuous treatment with EGFR-TKIs after disease progression was significantly higher than that in patients who stopped EGFR-TKI treatment at diagnosis of disease progression. Continuous treatment with EGFR-TKI following disease progression may therefore influence the frequency of *EGFR* T790M mutations in rebiopsy samples.
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